» Articles » PMID: 37658729

Long-term Cost-effectiveness of a Melanoma Prevention Program Using Genomic Risk Information Compared with Standard Prevention Advice in Australia

Overview
Journal Genet Med
Publisher Elsevier
Specialty Genetics
Date 2023 Sep 2
PMID 37658729
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Evidence indicates that a melanoma prevention program using personalized genomic risk provision and genetic counseling can affect prevention behaviors, including reducing sunburns in adults with no melanoma history. This analysis evaluated its longer-term cost-effectiveness from an Australian health system perspective.

Methods: The primary outcome was incremental cost effectiveness ratio (ICER) of genomic risk provision (intervention) compared with standard prevention advice. A decision-analytic Markov model was developed using randomized trial data to simulate lifetime cost-effectiveness. All costs were presented in 2018/19 Australian dollars (AUD). The intervention effect on reduced sunburns was stratified by sex and traditional risk, which was calculated through a validated prediction model. Deterministic and probabilistic sensitivity analyses were undertaken for robustness checks.

Results: The per participant cost of intervention was AUD$189. Genomic risk provision targeting high-traditional risk individuals produced an ICER of AUD$35,254 (per quality-adjusted life year gained); sensitivity analyses indicated the intervention would be cost-effective in more than 50% of scenarios. When the intervention was extended to low-traditional risk groups, the ICER was AUD$43,746 with a 45% probability of being cost-effective.

Conclusion: Genomic risk provision targeted to high-traditional melanoma risk individuals is likely a cost-effective strategy for reducing sunburns and will likely prevent future melanomas and keratinocyte carcinomas.

Citing Articles

Cost-effectiveness analysis and return on investment of SunSmart Western Australia to prevent skin cancer.

Collins L, Minto C, Ledger M, Blane S, Hendrie D Health Promot Int. 2024; 39(4).

PMID: 39110010 PMC: 11333957. DOI: 10.1093/heapro/daae091.


The Cost-Effectiveness of Primary Prevention Interventions for Skin Cancer: An Updated Systematic Review.

Collins L, Gage R, Sinclair C, Lindsay D Appl Health Econ Health Policy. 2024; 22(5):685-700.

PMID: 38861109 DOI: 10.1007/s40258-024-00892-2.